| Identification | Back Directory | [Name]
Cyclobutanecarboxylic acid, 3-[2-[4-(8-chloro-4-oxo-4H-1-benzopyran-2-yl)phenoxy]ethoxy]- | [CAS]
2919019-72-8 | [Synonyms]
Cyclobutanecarboxylic acid, 3-[2-[4-(8-chloro-4-oxo-4H-1-benzopyran-2-yl)phenoxy]ethoxy]- | [Molecular Formula]
C22H19ClO6 | [MOL File]
2919019-72-8.mol | [Molecular Weight]
414.84 |
| Chemical Properties | Back Directory | [Boiling point ]
628.4±55.0 °C(predicted) | [density ]
1.43±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | [form ]
Solid | [pka]
4.46±0.40(predicted) | [color ]
White to yellow |
| Hazard Information | Back Directory | [Uses]
ccc_R08 is a non-cytotoxic and orally active cccDNA inhibitor that reduces cccDNA levels in the liver of HBV-infected mice. ccc_R08 can be used in the study of HBV virus (hepatitis B virus) infection[1][2]. | [in vivo]
ccc_R08 (20 mg/kg; p.o.; twice per day for 2 weeks) clears cccDNA from the liver of HBVcircle mice[1].
ccc_R08 (10, 15, 20, 30 mg/kg; p.o.; twice per day for 2 weeks) significantly decreases the serum level of pgRNA in a dose-dependent manner, and the reduction in pgRNA is quantitatively correlated with that in liver cccDNA at different doses[1]. | Animal Model: | HBVcircle mouse model [1]. | | Dosage: | 20 mg/kg | | Administration: | Oral administration; twice per day for 2 weeks | | Result: | Led to the clearance of cccDNA from HBVcircle mouse livers. |
| Animal Model: | HBVcircle mouse model [1]. | | Dosage: | 10, 15, 20, 30 mg/kg | | Administration: | Oral administration; twice per day for 42 days | | Result: | Led to a sustained reduction in the serum levels of pgRNA. |
| [References]
[1] Wang L, et al. Discovery of a first-in-class orally available HBV cccDNA inhibitor. J Hepatol. 2022 Dec 29:S0168-8278(22)03466-3. DOI:10.1016/j.jhep.2022.12.014
[2] Ligat G, et al. Targeting Viral cccDNA for Cure of Chronic Hepatitis B. Curr Hepatol Rep. 2020 Sep;19(3):235-244. DOI:10.1007/s11901-020-00534-w |
|
|